Compile Data Set for Download or QSAR
maximum 50k data
Found 65 Enz. Inhib. hit(s) with all data for entry = 1012
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302867((2S,4R)-1-(2-(3- acetyl-6- (trifluoromethylsulfon-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302872((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302874((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302878((2S,4R)-1-(2-(3- acetyl-5-(5- fluoropyridin-3- yla...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302879((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302880((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302881((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302882(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302883(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302884(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302889(1-(2-((2S,4R)-2-(6- chloropyridin-2- ylcarbamoyl)-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302893(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302900(1-(2-((2S,4R)-2-(2'- chloro-2- fluorobiphenyl-3- y...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302928((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302930((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302931((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303009((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303010((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303011((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303012((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303013((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303015((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303024((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303026((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303028((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303030((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303033((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303037((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303038((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303039((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303040((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303041((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303042((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303043((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303051((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303052((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303053((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303054((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303057((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303058((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303059((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303060((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50: <1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302863((2S,4R)-1-(2-(N-(3- acetyl-1-(2-((2S,4R)- 2-(3-chl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303016((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303049((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303048((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303047((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303046((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM303025((2S,4R)-1-(2-(3- acetyl-5-(pyrimidin-5- ylamino)-1...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetComplement factor D(Homo sapiens (Human))
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM302902(((3-acetyl-1-(2- ((2S,4R)-2-(2'-chloro- 2-fluorobi...)
Affinity DataIC50:  5.50E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 65 total ) | Next | Last >>
Jump to: